

RESEARCH ARTICLE

Single-cell transcriptome analyses reveal critical roles of RNA splicing during leukemia progression

Baohong Wu¹✉, Xuelan Chen¹✉, Xiangyu Pan¹✉, Xintong Deng¹, Shujun Li¹, Zhongwang Wang¹, Jian Wang¹, Dan Liao¹, Jing Xu¹, Mei Chen¹, Chengjian Zhao², Zhihong Xue², Yuan Wang², Ting Niu¹, Jingwen Lin², Lu Chen^{2,3*}, Yu Liu^{1,2*}, Chong Chen^{1,2*}

1 Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, **2** State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China, **3** Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China

✉ These authors contributed equally to this work.

* luchen@scu.edu.cn (LC); yuliuscu@scu.edu.cn (YL); chongchen@scu.edu.cn (CC)



OPEN ACCESS

Citation: Wu B, Chen X, Pan X, Deng X, Li S, Wang Z, et al. (2023) Single-cell transcriptome analyses reveal critical roles of RNA splicing during leukemia progression. *PLoS Biol* 21(5): e3002088. <https://doi.org/10.1371/journal.pbio.3002088>

Academic Editor: Connie J. Eaves, B.C. Cancer Agency, CANADA

Received: October 5, 2022

Accepted: March 21, 2023

Published: May 2, 2023

Copyright: © 2023 Wu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All scRNA-seq and RNA-seq data in this study are deposited in NCBI Gene Expression Omnibus under accession number GSE142645. The analysis code can be found at GitHub (<https://github.com/pangxueyu233/Super-RNA-splicing-entropy-drives-stepwise-leukemogenesis>). All flow cytometry data for **S1 Fig** are deposited in the FlowRepository database under accession number FR-FCM-Z64U and FR-FCM-Z64T.

Funding: This work was supported by the National Natural Science Foundation of China (82130007 to

Abstract

Leukemogenesis is proposed to be a multistep process by which normal hematopoietic stem and progenitor cells are transformed into full-blown leukemic cells, the details of which are not fully understood. Here, we performed serial single-cell transcriptome analyses of preleukemic and leukemic cells (PLCs) and constructed the cellular and molecular transformation trajectory in a *Myc*-driven acute myeloid leukemia (AML) model in mice, which represented the transformation course in patients. We found that the *Myc* targets were gradually up-regulated along the trajectory. Among them were splicing factors, which showed stage-specific prognosis for AML patients. Furthermore, we dissected the detailed gene network of a tipping point for hematopoietic stem and progenitor cells (HSPCs) to generate initiating PLCs, which was characterized by dramatically increased splicing factors and unusual RNA velocity. In the late stage, PLCs acquired explosive heterogeneity through RNA alternative splicing. Among them, the *Hsp90aa1^{hi}* subpopulation was conserved in both human and mouse AML and associated with poor prognosis. Exon 4 skipping of *Tmem134* was identified in these cells. While the exon skipping product *Tmem134β* promoted the cell cycle, full-length *Tmem134α* delayed tumorigenesis. Our study emphasized the critical roles of RNA splicing in the full process of leukemogenesis.

Introduction

Tumorigenesis, a process to accumulate enough genetic alterations for normal cells to be transformed into malignant cells, can take decades in patients [1–5]. Similarly, leukemogenesis is conceptualized as the multistage process for normal hematopoietic stem and progenitor cells (HSPCs) to become full-blown leukemic cells [6,7]. It has been shown that largely normal

YL, 82170171 to CC), the Sichuan Science and Technology Program (2021YFS0027 to LC, 2020YFQ0059 to CC, 2018JZ0077 to YL), the 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC21009 to YL and ZYGD22012 to YL), the Sichuan University Postdoctoral Interdisciplinary Innovation Fund to XC, the Post-Doctor Research Project, West China Hospital, Sichuan University (2023HXBH019 to BW and 2023HXBH033 to XC), the China Postdoctoral Science Foundation (2022M722272 to JX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CH, clonal hematopoiesis; CNV, copy number variation; DEG, differentially expressed gene; GSEA, gene set enrichment analysis; GSVA, gene set variation analysis; HSPC, hematopoietic stem and progenitor cell; LSC, leukemic stem cell; MDS, myelodysplastic syndrome; MFI, mean fluorescence intensity; MPN, myeloproliferative neoplasm; PLC, preleukemic and leukemic cell; PSI, percent-splice-in; scRNA-seq, single-cell RNA sequencing; SF, splicing factor; TPS, tipping point signature; UMI, unique molecular identifier; WBM, whole bone marrow.

clonal hematopoiesis (CH) can progress into low-risk myelodysplastic syndrome (MDS) and then high-risk MDS or myeloproliferative neoplasm (MPN), eventually leading to full-blown acute myeloid leukemia (AML) [7]. However, AML is among the human malignancies with the lowest mutation burdens [8], and there is accumulating evidence suggesting that the majority of genetic alterations exist in preleukemic conditions such as CH and MDS [9–12]. Therefore, we wondered whether molecular rewiring other than mutations plays a significant role during leukemogenesis. Recent advances in omics studies, especially single-cell RNA sequencing (scRNA-seq), combined with our murine AML model, have provided unique opportunities to reveal the trajectory of leukemogenesis and further molecular characterization after acquiring initiating mutations.

In this study, we constructed a transformation route for HSPCs into full-blown AML by analyzing the transcriptomes of 18,900 preleukemic and leukemic cells at different stages and revealed progressively abnormal RNA splicing during leukemogenesis.

Results

Construction of a single-cell transcriptomic map of stepwise leukemogenesis in a murine AML model

Since *MYC* is frequently amplified and/or overexpressed in human AML (13%) and in MDS which may develop AML later and was previously called as preleukemia, we constructed an *Myc*-induced murine AML model (S1A–S1C Fig) [13]. To dissect the whole process of leukemogenesis, we performed a series of scRNA-seq analyses of bone marrow (BM) cells from mice transplanted with leukemogenic HSPCs at different stages (S1D Fig). All the recipient mice developed full-blown AML approximately 8 weeks after transplantation with minimal variation (S1E Fig). The leukemic cells could be identified by the expression of GFP, which was linked with *Myc*. A majority (80.3%) of the bone marrow in all transplanted mice was leukemia cells that expressed markers of myeloid lineage (B220-; CD3-; Mac-1+; c-Kit+), and over time, the proportion of myeloid cells increased (S1F and S1G Fig). Peripheral blood smears showed step-by-step leukocytosis with increased blasts (S1H Fig). The histological analysis showed that the resulting mouse AML recapitulated the features of human disease (S1I Fig). During leukemogenesis, we harvested the initiating *Myc*-overexpressing HSPCs (pretransplanted, T₀), preleukemic BM cells at 2 weeks (T₁), 4 weeks (T₂) after transplantation, and full-blown AML BM cells (T₃, 8 weeks after transplantation) for 10× Genomics scRNA-seq analyses, and a total of 41,078 cells were retained for analysis. Two independent repeats for each time point were highly similar to each other (S2A Fig).

Accordingly, we calculated the UMAP plot of all these preleukemic and leukemic cells (PLCs) together with normal BM cells (Fig 1A). The normal cell subpopulations were clustered by their distinct gene signatures, and the remaining GFP-positive cells were defined as the PLC subtype (S2B Fig). While all the normal cell lineages from each time point largely overlapped, PLCs displayed a shift from being close to neutrophils to being close to HSPCs on the UMAP (Fig 1B). The ratios of normal populations gradually decreased, while those of PLCs increased over time (S2C Fig).

Since it has been proposed that uncontrolled proliferation and blocked differentiation are 2 major mechanisms of leukemogenesis [7], we analyzed the cell cycle and differentiation status of PLCs. The results showed a gradual increase in the cell cycle for PLCs from T₀ to T₃ (Fig 1C). PLCs also acquired progressively increased differentiation blocks, as indicated by reduced differentiation scores and enhanced stemness scores from T₀ to T₃ (Fig 1D). We also found that the number of unique molecular identifiers (UMIs) and genes progressively increased in GFP-positive cells, while those of GFP-negative cells did not, which was consistent with a




Fig 1. Serial scRNA-seq analyses revealing the landscape of progressive leukemogenesis. (A) UMAP plot of normal cells and PLCs for all 9 samples at 5 time points (normal whole bone marrow (2×), T0 (before transplant, 1×), T1 (2 weeks after transplant, 2×), T2 (4 weeks after transplant, 2×), and T3 (8 weeks after transplant, 2×)) of leukemogenesis. Cells are colored according to *Myc-GFP* expression (upper left corner). (B) UMAP plot of normal cells and PLCs during leukemogenesis ordered by time point. (C) Density scatter plots showing G2M scores and S scores in PLCs during leukemogenesis. (D) Density scatter plots showing differentiation and stemness signature scores in PLCs during leukemogenesis. (E) Bar graph showing the number of UMI counts of *Myc-GFP*-positive and *Myc-GFP*-negative cells at 3 time points; *p* values were calculated by the Wilcoxon signed-rank test. (F) The heatmap displaying the normalized expression levels of high-risk MDS, MDS_AML, and AML signatures in PLCs at each time point. The underlying data for Fig 1C, 1D, 1E and 1F can be found in [S1 Data](#). AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; PLC, preleukemic and leukemic cell; scRNA-seq, single-cell RNA sequencing; UMI, unique molecular identifier.

<https://doi.org/10.1371/journal.pbio.3002088.g001>

previous report that RNA abundance is associated with elevated expression of stem genes [14] (Figs 1E and S2D and S2E). Overall, we delineated a single-cell landscape of leukemogenesis that recapitulated the stepwise transition of this disease.

Clinically, more than 30% of MDS cases progress to AML. To visualize the molecular switches in PLCs during leukemogenesis, we performed correlation analysis of the transcriptome between PLC populations at different time points and patients with high-risk MDS, MDS-AML, and de novo AML [15]. Of note, the gene signature of T₁ PLCs was highly expressed in patients with high-risk MDS, that of T₂ PLCs was highly expressed in AML

patients who developed from MDS and that of T₃ PLCs was highly expressed in de novo AML (Fig 1F). The correlation of the stepwise molecular switches of PLCs with those of patients suggested that the molecular trajectory of PLC transformation in mice represented a potential mechanism of leukemogenesis from MDS to AML patients.

Progressively deteriorated RNA splicing abnormality during leukemogenesis

To dissect the molecular events underlying stepwise leukemogenesis, we performed gene set variation analysis (GSVA) for specific pathways of PLCs of each stage. We found that the *Myc* target genes gradually increased from T₀ to T₃, along with genes involved in oxidative phosphorylation and DNA repair, and the genes of the p53 pathways gradually decreased over time, all of which were consistent with the gradually increased aggressiveness of PLCs over time (Fig 2A).

Since *myc* was the sole driver in this AML model, we first checked the expression levels of *Myc*. We found that the expression of either ectopic or endogenous *Myc* was not constitutively increased from T₀ to T₃ (S3A Fig). However, we observed that the expression levels of *Myc* targets constitutively increased from T₀ to T₃ (S3B Fig). Since the expression level of *Myc* itself was not progressively changed in PLCs, it was unlikely that the increase in *Myc* targets was just a selection of cells with high levels of *Myc*, which further suggested that stepwise leukemogenesis was not a result of simply selecting *Myc* expression. Importantly, by analyzing the transcriptome of the TCGA AML cohort, we found that the signature of *Myc* target, but not the expression of *Myc* itself, was associated with the poor prognosis of AML patients (S3C Fig).




Fig 2. The *Myc* targets, not *Myc*, triggered a progressively deteriorating RNA splicing abnormality during leukemogenesis. (A) Heatmap showing GSVA scores of hallmark pathways at each time point during leukemogenesis. (B) The top 10 KEGG pathways of *Myc* targets detached in PLCs. (C) The box plot showed the relative expression levels of SFs in PLC during leukemogenesis; p values were calculated by the Wilcoxon signed-rank test. (D) Heatmap showing the relative expression levels of 4 subtypes of MYC targets involved in high SFs (rows) during leukemogenesis (columns) in murine AML. (E) Kaplan-Meier survival curves of TARGET-AML patients with low or high SFs expression at T₀, T₁, T₂, and T₃. The p value was calculated by the log-rank test. The underlying data for Fig 2C and 2E can be found in S1 Data. AML, acute myeloid leukemia; GSVA, gene set variation analysis; PLC, preleukemic and leukemic cell; SF, splicing factor.

<https://doi.org/10.1371/journal.pbio.3002088.g002>

Furthermore, the KEGG analysis of the *Myc* target genes revealed that the spliceosome pathway was the most enriched among the *Myc* targets in PLCs, along with the cell cycle pathway and RNA transport pathway [16] (Fig 2B). The expression level of splicing factors gradually increased from T₀ to T₃ (Fig 2C), and stage-specific splicing regulatory factors (SFs) were identified by gene expression (Figs 2D and S3D). We found that the expression of these stage-specific SFs associated with PLCs, but not those associated with normal cells, had prognostic value in human AML patients, and the prognostic value of PLC SFs progressively increased from T₁ to T₃ (Fig 2E). Taken together, these data suggested that aggressively increased expression of splicing factors, independent of the *Myc* expression level, might underlie the progression from preleukemic to fully transformed leukemia in our stepwise model of leukemogenesis.

Abnormal RNA splicing kinetics distinguish leukemogenic initiating cells from their normal counterparts at the tipping point

Diverging from the normal development route is one of the critical steps at the initiation of tumorigenesis [17]. In the landscape of leukemogenesis, we observed a diverging point where HSPCs would differentiate into GMP cells or be transformed into GMP-like preleukemic cells (Fig 3A). Of note, the progenitor-like and GMP-like AML patients' signatures are mostly expressing in our GMP-like preleukemic cells [18] (S4A Fig). GFP⁺ cells contained quite a lot of HSC population at the start T₀ that were reduced to almost zero at the end time point T₃ (S4B Fig). Consistently, the differentiation route from HSPCs to GMP cells was characterized by reduced expression of leukemia signature genes and increased expression of myeloid/neutrophil lineage genes, while in sharp contrast, the transformation route from HSPCs to GMP-like cells displayed increased expression of leukemia signature genes and decreased expression of differentiation genes (Fig 3B). The kinetics of the expression of GMP-specific and GMP-like-specific genes over pseudotime indicated that there was a fate-determining tipping point for *Myc*-expressing HSPCs to either the GMP differentiation route or GMP-like leukemogenesis route (Fig 3C).

Given the importance of RNA splicing during the whole leukemogenesis process, we analyzed RNA splicing kinetics at the tipping point of leukemogenesis by RNA velocity, which has been suggested to indicate developmental potential and cellular dynamics [19]. Consistent with the differentiation tendency of HSPCs into GMPs, HSPCs displayed relatively stationary RNA velocity, and GMPs had high velocity. There was a strong directional flow from HSPCs to GMP. Strikingly, the RNA velocity of GMP-like cells was more stationary than that of HSPCs, and more importantly, the directional flow was from GMP-like cells to HSPCs, which indicated that GMP-like cells at the tipping point may have more potential than HSPCs (Fig 3D). Importantly, we found that at the onset of leukemogenesis, GMP-like cells did not gain a significantly increased AML or leukemic stem cell (LSC) signature (Fig 3E) compared to HSPCs. However, we observed a significant decrease in the expression of RNA SFs from HSPCs to GMPs but a significant increase from HSPCs to GMP-like cells (Fig 3F). These active splicing factors might give preleukemic cells a selection pool for leukemia-promoting molecules.

NPM1 at the tipping point is involved in leukemogenesis

To identify the key signatures leading to the binary cell fate choice at the tipping point, we analyzed the differential expression of genes on the 2 evolutionary routes and then defined the intersection between the low-expressing gene set 2 in the GMP lineage and the high-expressing gene set 4 in the GMP-like lineage as tipping point signatures (TPS), with a total of 30 genes




Fig 3. A tipping point for normal differentiation and malignant transformation during leukemogenesis. (A) UMAP plot of the tipping point for *Myc*-GFP-positive HSPCs, GMPs, and GMP-like cells. (B) The UMAP plots showing the expression levels of GMP classical markers, *Klf2* and *Cd177* (top), and GMP-like markers, *Mif* and *Ncl* (bottom). (C) The differentiation trajectory from HSPCs to GMP cells (top) and the transformation trajectory from HSPCs to GMP-like cells (bottom) calculated by Slingshot. (D) The RNA velocity at the tipping point. (E) The box plots showed the expression levels of the AML and LSC signatures in HSPCs, GMPs, and GMP-like cells; *p* values were calculated by the Wilcoxon signed-rank test. (F) The box plots showed the expression levels of the SF signature in HSPCs, GMPs, and GMP-like cells; *p* values were calculated by the Wilcoxon signed-rank test. The underlying data for Fig 3C, 3E and 3F can be found in [S1 Data](#). AML, acute myeloid leukemia; HSPC, hematopoietic stem and progenitor cell; LSC, leukemic stem cell; SF, splicing factor.

<https://doi.org/10.1371/journal.pbio.3002088.g003>

(S4C and S4D Fig). We characterized the TPS pattern in the GMP lineage and GMP-like lineage and found that the KEGG_RIBOSOME pathway associated with tumorigenesis also conformed to this pattern (S4E and S4F Fig).

Furthermore, CRISPR/Cas9 gene editing was used to verify and screen out genes that affect the differentiation and stemness of *Myc*-overexpressing HSPCs at the tipping point of malignant transformation. To identify specific genes promoting the differentiation of HSPCs, we ranked the sgRNAs by differences in the mean fluorescence intensity (MFI) of Mac-1 or c-Kit staining and the proportion of Mac-1+ or c-Kit+ cells. Based on all detection indicators, *Npm1* and *Phgdh* were finally selected as key molecules for inducing HSPCs malignant transformation during leukemogenesis (S4G and S4H Fig). In addition, the characteristic molecular interaction network analysis showed that *Npm1* was a key node gene in the GMP-like cells, as both the differentially activated module gene and differentially expressed gene (DEG) in the GMP-like cells suggested that *Npm1* might be a key player in leukemogenesis (Fig 4A). As expected, *Npm1* mRNA was gradually up-regulated in the transformation route and malignant progression, but gradually down-regulated in the differentiation route, consistent with our TPS pattern (Figs 4B and S4I). The abnormal expression of *NPM1* has been reported to be involved in human leukemogenesis [20], and consistent with the up-regulation of *Npm1* expression in GMP-like cells, *NPM1* was also significantly up-regulated in AML patients compared to




Fig 4. *Npm1* acted as a tipping point signature to promote AML. (A) The molecular interaction networks showing the node genes in GMP-like cells. Red represents DAMGs and DEGs, simultaneously; orange represents DEGs; green represents DAMGs; gray represents connecting Steiner genes. (B) The relative expression of *Npm1* along the differentiation (left) and transforming (right) trajectories. (C) The box plot showed the expression levels of *NPM1* in TCGA-LAML and normal samples. **** $p_{adj} < 0.001$; p values were calculated by Wilcoxon signed-rank test. (D) The Kaplan–Meier survival curve of recipient mice transplanted with *Myc*-GFP HSPCs harboring sgScramble or sg*Npm1*. ** $p < 0.01$ (log-rank test). (E) The bar graphs showed the MFI of differentiated cells (left) and stem cells (right) at 2 days, 4 days, and 6 days in sg*Npm1* samples compared to scramble samples. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; P values were calculated by unpaired parametric t test. (F) Scatter plot showing differentiation and stemness signature scores in sg*Npm1* and sgScramble samples. Measured by RNA-seq. (G) The box plot showed the expression levels of the GMP-like signature (left) and GMP signature (right) in sg*Npm1* and sgScramble samples. * $p < 0.05$, ** $p < 0.01$, p values were calculated by Chi-squared test. (H) The KEGG pathways enriched in sgScramble samples compared to sg*Npm1* samples (top). KEGG pathways enriched in sg*Npm1* samples compared to sgScramble samples (bottom). (I) GSEA showing the negative enrichment of HALLMARK_MYC_TARGETS_V1 and HALLMARK_MRNA_SPLICING in sg*Npm1* cells compared to sgScramble cells. (J) GSEA showing the negative and positive enrichments of GMP-like and GMP signatures in sh*NPM1* K562 cells compared to shREN cells. The underlying data for Fig 4C–4J can be found in [S1 Data](#). AML, acute myeloid leukemia; DAMG, differentially activated module gene; DEG, differentially expressed gene; GSEA, gene set enrichment analysis; HSPC, hematopoietic stem and progenitor cell; MFI, mean fluorescence intensity.

<https://doi.org/10.1371/journal.pbio.3002088.g004>

normal samples (Fig 4C). Therefore, we performed further functional studies of *Npm1* to verify its effect on the development of leukemia.

To validate the function of *Npm1* in leukemogenesis, we disrupted it in *Myc*-overexpressing HSPCs by CRISPR/Cas9 (S5A–S5C Fig) and found that *Npm1* loss significantly extended the latency of *Myc*-driven AML in mice (Fig 4D). Consistently, *Npm1* deficiency promoted the differentiation of HSPCs in vitro, as indicated by significantly increased expression of the

differentiation marker Mac-1 and decreased levels of the stem cell marker c-Kit (Fig 4E). Transcriptomic analysis by RNA-seq also showed that *Myc*-overexpressing HSPCs promoted cell differentiation while decreasing stemness, with more GMP gene signatures and fewer GMP-like signatures after the deletion of *Npm1* (Fig 4F and 4G). KEGG also showed that cell differentiation and apoptosis pathways were enriched in *Npm1*-deficient tumor-initiating cells (Fig 4H). GSEA indicated that the MYC_TARGETS_V1 and MRNA_SPLICING up-regulated genes were significantly negatively enriched in HSPCs with *sgNpm1* compared to those with *sgScramble*, which corroborates our previous analysis of global molecular regulatory events behind the evolution of leukemia from T0 to T3 (Fig 4I). Consistent with our data, the GMP gene signature was significantly positively enriched in *NPM1*-deficient human leukemic cells compared to control shREN cells, and the GMP-like gene signature was significantly negatively enriched, suggesting that *NPM1* might be a driver of leukemia (Fig 4J).

Phgdh, although rarely reported in AML, was another top gene in the tipping point of GMP-like cells. Its expression was up-regulated along the transformation route but down-regulated in the differentiation route (S5D Fig). Furthermore, *Phgdh* disruption promoted the differentiation of HSPCs (S5E Fig). We also observed that *Myc*-overexpressing HSPCs reduced the GMP-like gene signature, cell stemness and the cell cycle after *Phgdh* deletion (S5F and S5G Fig). KEGG also showed that lineage differentiation pathways were significantly enriched in *Phgdh*-deficient preleukemia cells, and GSEA showed that the MYC_TARGETS_V1 and MRNA_SPLICING up-regulated genes were also significantly negatively enriched in HSPCs with *sgPhgdh* (S5H and S5I Fig). High expression of *PHGDH* was associated with poor prognosis in AML patients (S5J Fig). We also have observed up-regulated expression of *NPM1* and *PHGDH* in most malignancies compared to normal samples (S5K and S5L Fig). As outlined above, our data suggested that the AML tipping point signatures, including *Npm1* and *Phgdh*, might be a critical driver for leukemia initiation at the tipping point.

RNA splicing creates explosive heterogeneity of leukemic cells

Once the PLCs went through the tipping point and embarked on the tumorigenesis route, they gradually gained malignancy and heterogeneity, which could be visualized on the URD map (S6A Fig). All these PLCs could be grouped into 5 major subpopulations, which were named after their top marker genes (Fig 5A and 5B). On the map were all the T0 cells at the “root,” followed by T1 and T2 cells, sequentially, at the “stem.” T3 cells were located at the crown and ended with multiple “branches” (Fig 5C). The expression of the human AML signature genes gradually increased along with the leukemogenesis “tree” (S6B Fig). The ratios of these subpopulations significantly varied among the time points, and *Hsp90aa1*^{hi} cells did not emerge until T3, suggesting that this subpopulation might be more aggressive than others (S6C Fig). Consistently, distinguished expression modules were identified in PLCs at different stages T0, T1, T2, and T3, suggesting that the molecular features of PLCs are changed during leukemogenesis (S6D Fig). The *Hsp90aa1*^{hi} population had the highest expression of stemness score and the *Npg*^{hi} population had the highest expression of differentiation score (S6E Fig). Moreover, the 5 clusters represented different differentiation stages: the *Hsp90aa1*^{hi} and *Ifitm3*^{hi} populations were more stemness and the *Npg*^{hi} population was well differentiated (S6F Fig). As expected, we found that these subpopulations displayed distinguishable gene signatures in the TCGA_LAML and TARGET_AML databases, and the hazard ratio calculated that the *HSP90AA1*^{hi} subtype was significantly associated with high risk in human AML patients and *HSP90AA1* expressions were up-regulated in even most malignancies (S6G–S6K Fig). Consistently, we also found a positive correlation between the expression levels of *Npm1* or *Phgdh* gene and the *Hsp90aa1*^{hi} subpopulation signatures in tipping point cells (S6L Fig).




Fig 5. Explosive intraleukemia heterogeneity during leukemogenesis. (A) The force-directed layout maps showing leukemogenesis trajectories, colored by cell subtype. (B) The dot plot showed the expression of cell type-specific genes (column) across cell populations in PLCs. (C) The force-directed layout maps showing leukemogenesis, colored by time series. (D) The box plot showed the expression levels of SFs in each subpopulation; *p* values were calculated by the Wilcoxon signed-rank test. (E) UMAP plot of 165,333 single cells from bone marrow of 5 AML patients, colored by cell population. (F) The dot plot showed the expression of cell type-specific genes (column) across cell populations in AML patients. (G) Hierarchy clustering showing the orthologous murine (mmu) and

human (hsa) PLC subtypes at the single-cell level. (H) The box plot showed the expression levels of cell cycle signatures in PLC subtypes in AML patients; p values were calculated by the Wilcoxon signed-rank test. (I) The box plot showed the expression levels of SFs in PLC subtypes in AML patients; p values were calculated by the Wilcoxon signed-rank test. (J) The t-SNE plot showing the *Myc*-GFP-positive cells in T3, performed by Smart-seq2, colored by cell types. (K) Kaplan–Meier survival curves of TCGA-LAML patients with low or high *Hsp90aa1*^{hi} cell signatures. The p value was calculated by the log-rank test. The underlying data for Fig 5B, 5D, 5F and 5H–5K can be found in [S1 Data](#). AML, acute myeloid leukemia; PLC, preleukemic and leukemic cell; SF, splicing factor.

<https://doi.org/10.1371/journal.pbio.3002088.g005>

We further explored the potential molecular mechanisms underlying the heterogeneity, especially those promoting aggressiveness in the *Hsp90aa1*^{hi} subpopulation, and found that *Hsp90aa1*^{hi} cells expressed significantly higher levels of splicing factors than any other subpopulation (Fig 5D), suggesting that the splicing machinery generates leukemia intraheterogeneity and promotes its aggressiveness.

To validate the intraheterogeneity in human AML, we analyzed the single-cell transcriptomes of BM cells from 5 AML patients. The leukemic cells were recognized by referred copy number variations (CNVs) (S7A Fig). These AML cells could be divided into 4 distinct subpopulations (Fig 5E), and the ratios of these subpopulations significantly varied among these 5 patients (S7B Fig). Of note, the *HSP90AA1*^{hi} subpopulation shared the same marker genes, *HSP90AA1* and *PDLIM1*, with the *Hsp90aa1*^{hi} subpopulation in mouse AML. Similarly, the *TYROBP*^{hi} subpopulation expressed the same top marker genes, *TYROBP* and *SAT1*, as the *Tyrobp*^{hi} subpopulation in mouse AML (Fig 5F). Importantly, through unbiased hierarchy clustering according to their transcriptomes, we found that the human *HSP90AA1*^{hi} subpopulation was most similar to the mouse *Hsp90aa1*^{hi} subpopulation, the human *TYROBP*^{hi} subpopulation was most similar to the mouse *Tyrobp*^{hi} subpopulation, and the human *MPO*^{hi} and *SPINK2*^{hi} subpopulations were close to the mouse *Hes*^{hi} subpopulation (Fig 5G). Furthermore, the *HSP90AA1*^{hi} subpopulation was the most aggressive among all cells, as indicated by the highest cell cycle score, while the *TYROBP*^{hi} subpopulation had the slowest cell cycle in human AML (Fig 5H). Similar to those in mouse AML, the *HSP90AA1*^{hi} cells expressed the highest levels of splicing factors, while the *TYROBP*^{hi} cells expressed the lowest (Fig 5I). KEGG analysis showed that splicing pathways were also significantly enriched in the *HSP90AA1*^{hi} cell population (S7C Fig). The similarity of the intraheterogeneity and its associated molecular features between human and mouse AML suggested that our mouse AML model faithfully recapitulated the molecular and cellular characteristics of human disease and that abnormal RNA splicing generally promoted leukemic heterogeneity in various AML.

Exon 6 skipping of *Tmem134*, predominantly in the *Hsp90aa1*^{hi} subpopulation, promotes aggressiveness in AML

To deeply characterize abnormal RNA splicing events underlying leukemia heterogeneity, we performed single-cell RNA-seq analysis of 178 leukemic cells in T3 by Smart-seq2 instead of the 10× Genomics platform, which would be able to analyze the full length and more transcripts [21,22]. Based on their gene expression patterns, these cells were partitioned into 5 populations, and the t-SNE plot showed that the *Hsp90aa1*^{hi} subpopulation was separate from others (Figs 5J and S8A). Indeed, the high expression of the signature genes of the *Hsp90aa1*^{hi} cell population was also significantly associated with poor prognosis in human AML patients (Fig 5K).

Consistent with those analyzed by 10× Genomics, the signature genes of *Hsp90aa1*^{hi} cells were enriched in the RNA splicing pathway and DNA metabolic process pathway (S8B Fig). Furthermore, we found that all 5 major subtype events of alternative RNA splicing, including exon skipping, intron retention, alternative 5' splice site, alternative 3' splice site, and mutually exclusive exons, were increased in *Hsp90aa1*^{hi} cells compared with *Hsp90aa1*^{lo} cells (S8C Fig). These data validated the RNA splicing in the *Hsp90aa1*^{hi} subpopulation, which displayed more aggressiveness.

Among the alternatively spliced genes in *Hsp90aa1*^{hi} cells was transmembrane protein 134 (*Tmem134*), a putative transmembrane protein with 2 transmembrane domains on the C-terminus [23]. The full-length *Tmem134*, named *Tmem134α*, and exon 6 skipped *Tmem134*, named *Tmem134β* (Fig 6A). *TMEM134* is highly conserved in mice and humans, and importantly, the same exon skipping also occurred in human AML (Figs 6B and S8D). Furthermore, we also measured the PSI values of *TMEM134* exon 6 skipping in multiple cancers and found




Fig 6. The exon 6 skipping of *Tmem134*, associated with the most aggressive *Hsp90aa1*^{hi} subpopulation, promoted the cell cycle of leukemic cells. (A) Schematic diagram showing the frequent occurrence of homologous skipping events of *TMEM134* exon 6 in murine and human AML. (B) The percentages of *TMEM134* exon 6 skipping occurrences in normal and AML patients. Normal ($n = 3$), AML patients ($n = 8$). (C) The bar graph showed the *Tmem134* exon 6 skipping ratio in *Hsp90aa1*^{lo} and *Hsp90aa1*^{hi} cells. * $p < 0.05$ (Wilcoxon signed-rank test). (D) Semiquantitative PCR showing of the relative mRNA level of *TMEM134α* or *TMEM134β* in human AML cell lines. (E) Semiquantitative PCR showing of the relative mRNA level of *TMEM134α* or *TMEM134β* in 6 human AML patients. Overview of AML patients including gender, age, blast percent was shown above and genetic alterations was listed in S3 Table. (F) The survival curves of recipient mice transplanted with Myc-overexpressing c-Kit+ HSPCs overexpressing vector, *TMEM134α* or *TMEM134β*. ** $p < 0.01$ (log-rank test). (G) Growth curves of c-Kit+ HSPCs overexpressing vector, *TMEM134α* or *TMEM134β* under Myc at the indicated time points. ** $p < 0.01$, *** $p < 0.001$. P values were calculated by unpaired parametric t tests. (H) The growth curves of endogenous *Tmem134* KO mouse AML cells overexpressing vector, *TMEM134α* or *TMEM134β* at the indicated time points. * $p < 0.05$, ** $p < 0.01$. P values were calculated by unpaired parametric t tests. (I) Growth curves of Cas9+ AML cells transduced with sgScramble, sgExon6, or sgIntron6+7 at the indicated time points. ** $p < 0.01$, *** $p < 0.001$. P values were calculated by unpaired parametric t tests. (J) The growth curves of endogenous *TMEM134* KO THP-1 cells overexpressing vector, *TMEM134α* or *TMEM134β* at the indicated time points. ** $p < 0.01$, *** $p < 0.001$, p values were calculated by unpaired parametric t test. (K) The box plot showed the relative expression levels of *TMEM134α* up- and down-regulated genes compared to the vector in the *Hsp90aa1*^{lo} and *Hsp90aa1*^{hi} subpopulations. Each bar represents the mean \pm SD. **** $p < 0.0001$, p values were calculated using an unpaired parametric t test. (L) GSEA showing that the TAKDDA_TARGETS_of_NUP98_HOXA9_FUSION_UP gene set was negatively enriched in *TMEM134α* AML cells compared to vector AML cells. The underlying data for Fig 6B, 6C and 6F–6L can be found in S1 Data. AML, acute myeloid leukemia; GSEA, gene set enrichment analysis; HSPC, hematopoietic stem and progenitor cell.

<https://doi.org/10.1371/journal.pbio.3002088.g006>

that it happens in the most of them more or less, suggesting that it may have the general function in pan-cancer (S8E Fig). We found that exon 6 of *Tmem134* was skipped more in *Hsp90aa1*^{hi} cells than in other cells (Fig 6C). Importantly, exon 6 skipping of *TMEM134* was also validated in multiple human AML cell lines and 6 AML patients (Fig 6D and 6E). In addition, HSPCs with *TMEM134α* overexpression hindered leukemogenesis in our *Myc*-induced leukemia murine model compared to the empty vector, while *TMEM134β* significantly promoted leukemogenesis (Figs 6F and S9A). We observed that compared to *TMEM134α*, *TMEM134β*-overexpressing tumor-initiating cells proliferated rapidly in vivo with a strong growth advantage (S9B Fig). Similarly, *TMEM134β* promoted *Myc*-overexpressing HSPC growth, while *TMEM134α* inhibited HSPC growth ex vivo (Fig 6G).

Furthermore, we tested the potential effects of exon 6 skipping of *TMEM134* in *Myc*-induced AML cells ex vivo. To exclude the influence of endogenous *TMEM134* protein, we generated a *Tmem134* knockout *Myc* AML monoclonal cell line (i.e., M#8) with CRISPR/Cas9 and then introduced *TMEM134α* or *TMEM134β* cDNA into M8# by retrovirus (S9C–S9G Fig). The results showed that without endogenous *TMEM134*, exogenous *TMEM134α* significantly reduced the growth of leukemic cells compared to the empty vector, while *TMEM134β* significantly promoted the growth of leukemic cells (Fig 6H). In addition, we used 2 different strategies by abrogating the splicing site of exon 6 (sgExon6) or deleting the whole exon 6 (sgIntron5 combined with sgIntron6) for enforced exon 6 skipping of *Tmem134* in leukemia cells (S9H Fig). Both sgExon6 and sgIntron5+6 significantly increased the growth of AML cells (Fig 6I). Furthermore, we introduced synonymous mutated *TMEM134α/β* cDNA into the THP-1 and HL-60 cell line (2 kinds of human leukemia cell lines) with endogenous *TMEM134* knockout (S9I–S9K Fig). Consistently, *TMEM134α* significantly repressed the growth of human leukemia cells, and *TMEM134β* was promoted (Figs 6J and S9L). Then, we tested the in vivo effects of *TMEM134* exon 6 skipping on leukemia maintenance by transplanting leukemic cells harboring *TMEM134α* or *TMEM134β* into recipient mice. We found that recipients with *TMEM134α* had significantly extended survival (S9M Fig). Despite the short period of tumor development, we have not yet had time to observe the in vivo growth advantage of *TMEM134β*-overexpressing leukemia cells after the second transplant. Thus, exon 6 skipping of *TMEM134*, which likely abrogated the tumor suppression function of full-length *TMEM134*, drove aggressiveness in AML.

Consistently, EdU incorporation assays showed that the proliferation ratios of cells with sgExon6 or sgIntron5+6 were significantly higher than those of the control cells (S9N Fig). In both human and mouse AML, *TMEM134α* was significantly associated with a decreased cell cycle (S9O Fig). Transcriptomic analysis by RNA-seq also showed that *TMEM134α* significantly repressed the expression of cell cycle genes in AML (S9P Fig). The genes up-regulated by *TMEM134α* were expressed at significantly lower levels in *Hsp90aa1*^{hi} cells than in *Hsp90aa1*^{lo} cells, and in contrast, the genes down-regulated by *TMEM134α* were expressed at significantly higher levels in *Hsp90aa1*^{hi} cells than in *Hsp90aa1*^{lo} cells (Fig 6K). GSEA indicated that the NUP98-HOXA9 up-regulated genes were significantly negatively enriched in leukemia cells with *TMEM134α* compared to those with empty vector (Figs 6L and S9Q). These data strongly indicated that exon 6 skipping of *TMEM134* was critical for generating leukemia intraheterogeneity by promoting the aggressiveness of a subpopulation.

Discussion

Despite the long latency of tumorigenesis and potential opportunities for early diagnosis and treatment, our understanding of its underlying molecular mechanisms is very limited. In this study, we dissected the trajectory of leukemia initiation and progression at single-cell

resolution. The molecular features of this trajectory partially recapitulate those in patients. Stepwise tumorigenesis is characterized by gradual deterioration of differentiation block and uncontrolled proliferation [7,24]. At the very beginning, the cells of origin of cancer, HSPCs for AML, with the driver mutations, would go through a tipping point, a critical time for an irreversible choice between “normal” differentiation and malignant transformation. Furthermore, we found that heterogeneity, a hallmark of cancer, is largely acquired at the late stage of tumorigenesis. Our study describes the landscape of the molecular and cellular features of leukemogenesis driven by *Myc* overexpression. It would be interesting to test whether these features, including the tipping point and the explosive heterogeneity, would be applied to AML driven by other mutations and other cancers driven by MYC [25].

During the tumorigenesis trajectory, an unexpected observation is gradually increased RNA splicing, although the expression level of *Myc*, the initial driver, remains the same. Many of these abnormally regulated RNA splicing factors are shared in both mouse and human AML. The stage-specific splicing signatures display increased prognostic value over time. MYC can directly regulate the expression of many splicing genes [16,26]. RNA splicing is frequently involved in normal hematopoiesis and hematopoietic malignancies [27–29]. It would be important to explore how these splicing genes are stepwise up-regulated along the leukemogenesis trajectory without changes in the *Myc* level in future studies.

Comprehensively profiling abnormal RNA splicing events and investigating the functions of individual abnormally spliced genes in tumorigenesis are essential to better understand the roles of RNA splicing in the process. We show that exon 6 skipping of *TMEM134*, which is conserved in human and mouse AML, is significantly associated with poor prognosis. Furthermore, we demonstrate that *TMEM134α* and *TMEM134β* have opposite functions in malignancy. Interestingly, exon 6 encodes one of the 2 transmembrane domains of *TMEM134* [23]. Thus, this AML-associated exon skipping might disrupt the topology of the resulting protein. More work is needed to elucidate the mechanism of *TMEM134* exon 6 skipping for its function in AML.

Methods

Mice

C57BL/6 mice (Jackson Lab, Cat# 000664) were used as HSPC donor mice and transplantation recipients. CAG-Cas9-EGFP mice (Cat# 026179) were purchased from the Jackson Laboratory. All animal studies were approved by the Institutional Animal Care and Use Committees of Sichuan University (20220301026).

Murine AML model and AML cell line

Whole bone marrow (WBM) cells were obtained from 6-week-old C57/BL6 mouse tibiae, femora, and ilia bones and stained with mCD117 magnetic microbeads (Miltenyi Biotec, Cat# 130-091-224). Then, cKit⁺ HSPCs were enriched from MidiMACS Separator (Miltenyi Biotec, Cat# 130-042-302) and cultured in BCM medium (50% DMEM + 50% IMDM medium) supplemented with 20% FBS, 0.34% beta-mercaptoethanol, 10 ng/mL mIL3/mIL6, and 50 ng/mL mSCF. After 24 h of cultivation in the incubator, the retrovirus harboring pMIG-Myc was spin infected and centrifuged at 2,000 rpm for 1 h. After 24 h, cKit⁺ HSPCs with an approximately 20% infection ratio was injected via the tail vein into sublethally irradiated (5.5 Gy) 7-week-old female wild-type C57/BL6 mice (1×10^6 cells per mouse). Bone marrow-transplanted mice were maintained on medicated water (ciprofloxacin, 100 μg/mL) for 2 weeks and monitored for leukemogenesis. The mice were observed for a period of 7 to 8 weeks and were sacrificed by cervical dislocation when they became moribund. Statistical analysis of all survival data was

carried out using the log-rank test from Prism 9. AML cells were harvested from the bone marrow or spleen and cultivated into a cell line in BCM medium.

Cas9 AML cell line

pLentiCRISPV2 (Addgene plasmid #52961) was transduced into AML cells by lentivirus generated by the 293T cell line, and then Cas9-expressing AML cells were selected by puromycin administration (1 $\mu\text{g}/\text{mL}$) for 1 week.

Retroviral constructs

In Fig 6F and 6G, the cDNA elements overexpressing *TMEM134 α* and *TMEM134 β* were cloned into pMSCV-IRES-GFP-*Myc* (pMIG-*Myc*). In Figs 6H and 6J and S9L and S9M, the cDNA elements overexpressing *MYC*, *TMEM134 α* , and *TMEM134 β* (synthesized by Sangon Biotec, Shanghai) were cloned into pMSCV-IRES-GFP (pMIG) as previously reported [30] and pMSCV-IRES-mCherry (pMIC, constructed in house) retroviral vectors harboring a GFP/mCherry fluorescent reporter. Retroviruses were generated in the 293T cell line, and cDNA expression constructs were transduced into the cKit+ HSPC/AML cell line by a retrovirus.

CRISPRs

CRISPRs were designed at <https://www.atum.bio> and then cloned into V2TC (modified by pLentiCRISPV2; briefly, the Cas9 component in the vector was replaced with a mCherry fluorescent reporter). The target sgRNA sequences are shown in S1 Table. Lentiviruses were generated in 293T cell lines, and sgRNAs were transduced into Cas9-expressing cKit+ HSPCs/AML cell lines by lentivirus. The PCR primers are shown in S2 Table.

Cell growth curve

Cells were seeded at a concentration of 1×10^4 or 2×10^4 cells per well of a 96-well plate with 3 wells of each line. Cells were counted every 2 days, and subsequent cell counts were normalized to the seeding density after each count. All curves were obtained at least 2 independent times.

Cell proliferation and cell differentiation

Cell proliferation assays were performed with a Cell-Light EdU Apollo488 In Vitro Kit (RIBO-BIO, Cat# C10310-3). Briefly, cells were infected with viruses encoding *Tmem134 α* or *Tmem134 β* cDNA or empty vector. On day 3 after infection, cultured cells were stained with 1:4,000 EdU staining solution for 2 h, and then the cells were washed and fixed in 4% PFA. Cells were then incubated with 0.5% Triton X-100 and stained with Apollo reaction buffer.

For the cell differentiation experiment, Cas9-expressing HSPCs were infected with viruses encoding *Myc* and sgRNAs targeting scramble or *Npm1*. On days 2, 4, and 6 of infection, cultured cells were analyzed by staining for the differentiation surface marker Mac-1 (Biolegend, clone: M1/70, Cat# 101223)/Gr-1 (Biolegend, clone: RB6-8C5, Cat# 108430) and the stemness surface marker c-Kit (Biolegend, clone: 2B8, Cat# 105814). Double-positive and single-positive populations were gated following standard flow analysis to detect c-Kit and Mac-1/Gr-1 expression levels.

All flow cytometry analyses were performed with an LSRFortessa instrument (BD Biosciences).

Western blot

Cells were lysed with cell lysis buffer (Cell Signaling Technology, Cat#9803), and cell lysate was clarified by centrifugation, according to the manufacturer's protocol. Anti-NPM1 (Proteintech, clone: 4F12A3, Cat#60096-1-Ig), Anti-PHGDH (Proteintech, polyclonal, Cat#14719-1-AP), and Anti-TMEM134 (Invitrogen, polyclonal Cat#PA5-60492) were used for western blotting. Actin (Invitrogen, clone: BA3R, Cat#MA5-15739-HRP) was used to monitor equal loading.

RNA-seq analyses

RNA-seq libraries were constructed by an Illumina Stranded mRNA Sample Preparation Kit (NEB, Cat# E7770) according to the manufacturer's protocol and were sequenced by an Illumina NovaSeq 6000 sequencing machine with 150-bp paired-end reads. The RNA-seq reads were aligned to the mouse reference genome (GRCm38) by STAR_2.6.0a. Transcript abundance was normalized and measured by transcripts per kilobase million (TPM). GSEA was applied to show statistically significant similarities and differences between 2 given clusters by identifying a priori defined gene sets.

SMART-seq2 library preparation and sequencing

SMART-seq2 was performed on AML cells at T₃, following a modified SMART-seq2 protocol published previously [31]. The libraries were sequenced by an Illumina HiSeq X Ten Sequencing machine with 150-bp paired-end reads. The paired-end reads were aligned to the UCSC mm10 references by STAR_2.6.0a.

Single-cell collection, library preparation, and sequencing

WBM were isolated from mouse tibiae, femora, and ilia leg bones by crushing in 2% FBS (PBS) buffer, add 1:1,000 DNaseI and then translate into 15 mL BD tube, centrifuge at 1,200 rpm, RT for 3 min. Then, the supernatant was discarded, 3 mL of 1x ACK lysis buffer was added to resuspend the bone marrow pellet on ice for 3 to 5 min, and PBS (more than lysis buffer) was added to terminate the lysis reaction. The supernatant was discarded, and 0.04% PBS-BSA buffer was added to resuspend the cell pellet, which was then filtered through a 40- μ m cell strainer. More than 80% of the living cells in the sample and a density of living cells ranging from 600 to 1,200 cells/ μ l were preferable. Sample quality was measured using a Bio-Rad TC20 automated cell counter. Libraries were prepared using Chromium Single Cell 3' Reagent Kits v2 according to the manufacturer's protocol (10 \times Genomics) and were sequenced using Illumina NovaSeq 6000 sequencing.

Single-cell gene expression quantification

The ectopic *Myc* sequences were added to the reference genome, which could distinguish exogenous and endogenous cells in AML leukemogenesis. Cellranger (v2.1.1) was used to align clean reads with mm10. The Seurat (v.3.2.0) pipeline was applied to analyze scRNA data. Genes expressed in less than 5 cells were not considered, and cells that contained lower than 10% mitochondrial genes and contained at least 200 but not more than 6,000 genes were retained for the following analysis. Normalized data and scale data were generated from the Seurat workflow.

Batch effect reduction, dimension reduction, and unsupervised clustering

To integrate all the single cells from different samples for unsupervised clustering, integration anchor algorithms in Seurat were used to reduce the batch effect. The top 4,000 variable genes were used as highly variable genes by FindIntegrationAnchors, and an integrated assay matrix was used to build the nearest neighbor graph.

For dimension reduction, UMAP, t-SNE, diffusion-map, and force-directed graph were calculated on a batch-reducing matrix. UMAP and t-SNE were calculated by Seurat, and diffusion maps and force-directed graphs were calculated by URD. The cell subtypes were identified by the classic markers in previous studies [32,33].

To unify the identities of cell subtypes from a different platform, we used TransferData in Seurat. The 10× genomics data were used as the reference files, and smartseq2 data were used as query files to carry out transfer label pipelines. Then, unsupervised clustering algorithms were used to identify each cell identity in smartseq2.

Trajectory construction and pseudotime calculation

To calculate the trajectory and pseudotime on the UMAP plot of tipping point cells, the position matrix of scRNA data was extracted and processed to feed on Slingshot. Three hundred fixed points were performed to fit an approximate trajectory. In addition, the general additive model was used to identify the genes with dynamic expression based on pseudotime. The force-directed layout and pseudotime of PLCs were determined by URD packages.

GSVA, gene regulatory network analysis, and molecular interaction network analysis

GSVA was used to calculate the enrichment score per cell or sample. ClusterProfiler was used to enrich the GO and KEGG pathways. Pathway network analysis and visualization were performed on the modified cnetplot function. The molecular interaction network was calculated by RSCORE, with mouse-specific protein-protein interaction networks downloaded from BioGRID. Gene interaction matrix, generated from the gene expression matrix by R. SCORE function. The gene interaction network was visualized by the Steiner tree. The genes with highly significant differential expression and genes with highly significantly different network interactions are highlighted in the network map.

Generation of gene signatures and visualizations

Cell type-specific gene signatures were generated by the FindMarker/FindAllMarker function implemented in Seurat. Stemness gene signatures and differentiation gene signatures were generated from HSPC-specific expressed genes or neutrophil-specific expressed genes with significant statistical power. Gene sets of *Myc* targets and splicing factors were downloaded from the Molecular Signatures Database (MSigDB). The mean value of the log₂-transformation matrix was used to quantify the global activation of gene signatures or pathways in each cell/sample. The signature score was projected on the UMAP plot by using the modified FeaturePlot function.

Splicing events calculation

rMATS v4.0.2 was used to analyze splicing events on Smart-seq2 single-cell RNA-seq data. bam files were divided into 2 groups based on the cluster information. We summarized all splicing event types of rMATS results, including SE, A3SS, A5SS, RI, and MXE.

Cell cycle score calculation

To calculate the cell cycle score in each single cell, cell cycle phase signatures for humans and mice were obtained from the Seurat pipeline [34]. In each cell of single-cell data, CellCycleScoring with $nbin = 28$ was used to calculate G2 M scores and S scores. Cells with positive scores were divided into the G2 M phase or S phase, and their G1 scores were assigned to 0. For cells with negative scores, G1 scores were calculated by the following formula:

$$G1\ Scores = (-1) * \left(\frac{G2M\ Scores + S\ Scores}{2} \right).$$

After the G1 scores were calculated, the R package `ggpubr` was used for visualization. To calculate G1 scores in each bulk RNA-seq sample, the z score of the mean TPM value of G2 M signature scores and S phase signatures was evaluated.

Bulk data processing and signature identification in MDS and AML patients

Low-risk, high-risk MDS and MDS_AML patient data GSM2430698 [15] and AML patient data GSE1159 [35] were downloaded from the GEO database. We processed MDS patient data by the RNAs-seq workflow as previously mentioned. DESeq2 was used to identify the DEGs. Three types of signatures were obtained, including low-risk MDS signatures generated by comparing low-risk samples to normal samples ($p.adj < 0.05$ and $\log_2\text{FoldChange} > 3$), high-risk MDS signatures ($p.adj < 0.05$ and $\log_2\text{FoldChange} > 4$), and MDS-AML signatures ($p.adj < 0.05$ and $\log_2\text{FoldChange} > 4$) generated by the same kind of comparison. For AML patient data, DESeq2 was used to identify the DEGs ($p.adj < 0.05$ and $\log_2\text{FoldChange} > 1.5$). To project the patients' signature on mouse data, we used the R package `biomaRt` to convert the human genes to homologous mouse genes.

TCGA data analysis

Clinical information and transcriptome data of TARGET-AML and TCGA-AML were downloaded by the R package `TCGAbiolinks`. The percent-splice-in (PSI) value of TCGA-LAML was downloaded from TCGA SpliceSeq. Then, the clinical data were processed by filtering patients who could not match the transcriptome and clinical information. Patients whose follow-up days and days to death were not unknown were filtered.

To test the correlation of selected signature expression and patient survival, we calculated the signature scores in each patient based on the \log_2 transformation of the FPKM matrix. Then, `surv_cutpoint` was used to group patients based on the signature scores. Then, the `Surv` function and `survfit` function were used to fit reasonable survival curves, and the `ggsurvplot` function was used for visualization. The statistical power of survival differences was calculated by chi-squared distribution.

To test the correlation between splicing events and patient survival, the PSI value from TCGA SpliceSeq was used to divide patients into 2 groups. In the same way mentioned above, the survival curve and statistical power were visualized and quantified.

Identification of malignant cells with CNV estimation

To distinguish malignant cells from nonmalignant cells in human AML generated by 10× Genomics, we inferred large-scale chromosomal CNVs in each single cell based on moving averaged expression profiles across chromosomal intervals [36].

RNA velocity analysis

Velocityto was used to quantify the unspliced and spliced counts from BAM files in scRNA data by Run10x mode. The mm10 genome and mm10_rmsk references were downloaded from UCSC and used for alignment. RNA velocity analysis was quantified by velocityto. R program.

Supporting information

S1 Fig. Identification of leukemogenesis landscape. Related to Fig 1. (A) Copy number alteration of *MYC* in TCGA AML database. Red, Amplification; Pink, Gain; Gray, No alterations. (B) The plots showing the expression levels of *MYC* in normal samples and AML patients in TARGET_AML and TCGA AML cohorts. **** $p_{\text{adj}} < 0.0001$. p values were calculated by Wilcoxon test. Created with BioRender.com. (C) The plots showing the expression levels of *MYC* in normal samples and MDS patients generated from GSE107400. **** $p_{\text{adj}} < 0.0001$. p values were calculated by Wilcoxon test. (D) The overview of study design. (E) Kaplan–Meier survival curve of mice with *Myc*-GFP-induced murine AML model, ($n = 6$). (F) Representative flow cytometry profile of GFP-positive cells from bone marrow in T3 time point. (G) Flow cytometry profiles showing the percentage of lymphocyte and myeloid cells from peripheral blood in T1, T2, and T3 of leukemogenesis. X-axis is myeloid marker Mac-1; Y-axis is lymphocyte markers B220/CD3. (H) Blood smear of peripheral blood during T1 through T3 in *Myc*-GFP leukemic mouse. Scale bar: 10 μm . (I) Hematoxylin–eosin images of bone marrow (top), spleen (middle), and liver (bottom) during T1 through T3 in *Myc*-GFP leukemic mouse. Scale bar: 20 μm . The underlying data for S1B, S1C and S1E Fig can be found in S1 Data. (TIF)

S2 Fig. The characterization of murine AML during leukemogenesis. Related to Fig 1. (A) The UMAP plot of single cells for all 9 samples at 5 time points, colored by samples. (B) The heatmap showing the expression levels of cell type-specific genes among all cells, and classic markers were labeled on the right. (C) The line charts showing the dynamics percentage of each cell type during leukemogenesis. (D) Bar graph showing the number of genes in 3 times point; p values were calculated by Wilcoxon signed-rank test. (E) Bar graph showing the RNA concentration of *Myc*-GFP-positive cells and *Myc*-GFP-negative cells at T1 time point. *** $p < 0.001$, p values were calculated using an unpaired parametric t test. The underlying data for S2B–S2E Fig can be found in S1 Data. (TIF)

S3 Fig. MYC/MYC targets during leukemogenesis and stage-specific SFs in human MDS to AML. Related to Fig 2. (A) The box plot showing the expression levels of *Myc* at each time point during leukemogenesis; p values were calculated by Wilcoxon signed-rank test. (B) The box plot showing the expression levels of *Myc*_target at each time point during leukemogenesis; p values were calculated by Wilcoxon signed-rank test. (C) The Kaplan–Meier survival curves of TARGET-AML patients with low or high *MYC*/*MYC* targets; p value was calculated by log-rank test. (D) The heatmap showing the relative expression levels of 4 subtypes of *MYC* targets involved in splicing factors (columns), during leukemogenesis (rows), in human AML. The underlying data for S3A–S3C Fig can be found in S1 Data. (TIF)

S4 Fig. Differential expression between GMP and GMP like. Related to Fig 3. (A) The heatmap showing the expression levels of normal HSC progenitor, GMP, myeloid and AML HSC-like, progenitor-like, GMP-like makers in the Galen and colleagues, *Cell* 2019 (rows) in tipping point HSPC, GMP, and GMP-like cells (columns) [18]. (B) The UMAP plot of single cells at

tipping point stages split by samples and colored by cell annotation. (C) Heatmaps showing gene expression dynamics over pseudo time in GMP lineage (left) and GMP-like (right) lineage. Genes (row) are clustered and cells (column) are ordered according to the pseudo time. Gene set1: up-regulate genes in GMP lineage, Gene set2: down-regulate genes in GMP lineage, Gene set3: down-regulate genes in GMP-like lineage, Gene set4: up-regulate genes in GMP-like lineage. (D) Venn diagram showing the overlap among gene set1, gene set2, gene set3, and gene set4. (E) The tipping point signature expression trends along GMP lineage (left) and GMP-like lineage (right). Single cell colored by cluster annotation. (F) The Ribosome signature expression trends along GMP lineage (left) and GMP-like lineage (right). (G) Relative proportions of Mac-1+ (top) and of c-Kit+ (bottom) cell populations, measured by flow cytometry, in HSPCs infected with CRISPRs targeting tipping point genes or scramble. (H) Relative MFIs of Mac-1 (top) and of c-Kit (bottom) staining in HSPCs infected with CRISPRs targeting tipping point genes or scramble. (I) The box plot showing the expression levels of *Npm1/Phgdh* in PLCs at each time point during leukemogenesis. **** $p_{\text{adj}} < 0.0001$, p values were calculated by Wilcoxon test. The underlying data for S4G–S4I Fig can be found in [S1 Data](#). (TIF)

S5 Fig. *Phgdh* acted as another tipping point signature. Related to [Fig 4](#). (A) The schematic diagram showing the in vitro flow assay in Cas9 expressing HSPCs infected with *Myc-GFP* and sgRNA-mCherry. (B) T7 endonuclease I assay showed the sg*Npm1/Phgdh* efficiency in c-Kit+ cells derived from Cas9 expressing mouse. (C) Western blotting showing the protein levels of NPM1 and PHGDH in HSPCs edited with sg*Scr* or sg*Npm1/Phgdh*. (D) The relative expressions of *Phgdh* along with the differentiation (top) and transforming (bottom) trajectories. (E) The bar graphs showed the MFI of stem cells (left) and differentiated cells (right) at 2 days, 4 days, and 6 days, in sg*Phgdh* samples, compared to scramble samples. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, p values were calculated using an unpaired parametric t test. (F) The box plot showing the expression levels of GMP-like signature (left) and GMP signature (right) in sg*Phgdh* and sgScramble samples. * $p < 0.05$, ** $p < 0.05$, p values were calculated by likelihood ratio test. (G) The scatter plot showing differentiation/stemness signature scores (left) and G2M/S scores (right) in sg*Phgdh* and sgScramble samples. Measured by RNA-seq. (H) The KEGG pathways enriched in sgScramble samples, compared to sg*Phgdh* cells (top). The KEGG pathways enriched in sg*Phgdh* samples, compared to sgScramble cells (bottom). (I) GSEA showing the negative enrichment of HALLMARK_MYC_TARGETS_V1 and HALLMARK_MRNA_SPLICING in sg*Phgdh* cells, comparing to sg*Scr* cells. (J) Kaplan–Meier curve showing the survival of AML patients in TCGA stratified by the expression of *PHGDH*. P value was calculated by log-rank test. (K) The box plots showing the expression levels of *NPM1* in the normal GTEx samples and TCGA cohorts. * $p_{\text{adj}} < 0.05$, **** $p_{\text{adj}} < 0.0001$, n.s. not significant, p values were calculated by Wilcoxon test. (L) The box plots showing the expression levels of *PHGDH* in the normal GTEx samples and TCGA cohorts. * $p_{\text{adj}} < 0.05$, **** $p_{\text{adj}} < 0.0001$, n.s. not significant, p values were calculated by Wilcoxon test. The underlying data for S5E–S5L Fig can be found in [S1 Data](#). (TIF)

S6 Fig. The molecular characteristics of intertumoral heterogeneity. Related to [Fig 5](#). (A, B) The force-directed layout maps showing leukemogenesis trajectories, colored by pseudo time (A) and the expressions of human AML signature genes (B). (C) The bar graph showing the proportion of each cell type during leukemogenesis. (D) The heatmap showing the dynamics molecular features during leukemia progression. The key genes and top enriched gene sets were labeled. (E) The box plot showing the stemness scores and differentiation scores in PLCs. **** $p_{\text{adj}} < 0.0001$, p values were calculated by Wilcoxon test. (F) The heatmap showing the

expression levels of normal cell subtypes' signatures in PLCs. (G) Heatmap summarized the expression of 5 malignant cell subtypes from T3 in TCGA-LAML database annotated by clinical information including mutation counts, sex, blast percentages, WBC, diagnosis ages, FAB, and subgroups of patients. (H) Hazard ratio calculated using the expression of 5 malignant cell subtypes from T3 in TCGA-LAML database. Hazard ratios >1 indicate an increased risk of dying. While hazard ratios <1 indicate a beneficial prognosis for the patient; p values of each individual factor based on the multivariate analysis is depicted on the right of the figure with the values: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$. (I) Heatmap summarized the expression of 5 malignant cell subtypes in TARGET-AML database annotated by clinical information including mutation counts, sex, blast percentages, WBC, diagnosis ages, FAB, and subgroups of patients. (J) Hazard ratio calculated using the expression of 5 malignant cell subtypes from T3 in TARGET-AML database. Hazard ratios >1 indicate an increased risk of dying. While hazard ratios <1 indicate a beneficial prognosis for the patient; p values of each individual factor based on the multivariate analysis is depicted on the right of the figure with the values: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$. (K) The box plots showing the expression levels of *HSP90AA1* in the normal GTEx samples and TCGA cohorts. $*p_{\text{adj}} < 0.05$, $****p_{\text{adj}} < 0.0001$, n.s. not significant, p values were calculated by Wilcoxon test. (L) The scatter plots showing the correlation between the expression levels of *Npm1* or *Phgdh* and the *Hsp90aa1*^{hi} signatures. The underlying data for S6E and S6K Fig can be found in [S1 Data](#). (TIF)

S7 Fig. The similarity of the intra-heterogeneity and its associated molecular features between human and murine AML. Related to [Fig 5](#). (A) The heatmaps showed the results of inferCNV with hierarchical clustering in human AML. (B) The bar graph showing the proportion of 5 AML patients in each leukemia subtypes. (C) Top enriched KEGG pathways for differentially expressed genes in malignant cells. Node size represents gene ratio; node color represents p_{adjust} . p_{adjust} , adjusted p value. (TIF)

S8 Fig. Alternative splicing of *TMEM134* is common in murine and human malignant cells. Related to [Fig 6](#). (A) The t-SNE plot of T3 *Myc-GFP*-positive cells analyzed by Smart-seq2, colored by cell types. (B) The regulatory networks of signature genes in *Hsp90aa1*^{hi} cells. (C) The bar graph showing the numbers of differentially alternative splicing events between *Hsp90aa1*^{lo} and *Hsp90aa1*^{hi} cells. (D) The bar graph showing the skipping ratio of *Tmem134* exon6 in HSPC and AML. (E) The PSI values of exon6 skipping of *TMEM134* in TCGA pan-cancer samples. The underlying data for S8C–S8E Fig can be found in [S1 Data](#). (TIF)

S9 Fig. Alternative splicing of *TMEM134* promoted cell cycle. Related to [Fig 6](#). (A) Semi-quantitative PCR showed the relative mRNA expression of *TMEM134α* or *TMEM134β* in *c-Kit*⁺ HSPCs harboring vector, *TMEM134α* and *TMEM134β*. (B) Percentage of GFP-positive cells in peripheral blood collected from recipient mice with vector, *TMEM134α* and *TMEM134β* after 2- or 4-week transplantation. (C) T7 endonuclease I assay showed sg*Tmem134* efficiency in *Myc*-induced murine AML cells. (D) Sequence alignment result showing 2 bp insertion in one of the *Tmem134*^{-/-} AML clones. (E) Western blotting showing of *TMEM134* protein levels in *Tmem134* wild-type (*Myc* AML) or knockout leukemic cells (M8#). (F) Immunofluorescence staining of *TMEM134* protein in *Tmem134* wild-type (*Myc* AML) leukemic cells or M8#. (G) Semiquantitative PCR showed the relative mRNA expression of *TMEM134α* or *TMEM134β* in endogenous *Tmem134* KO mouse AML cells M8# harboring vector, *TMEM134α* and *TMEM134β*. (H) Semiquantitative PCR showed the relative mRNA

expression of *Tmem134α* or *Tmem134β* in *Myc*-induced leukemic cells harboring *sgScramble*, *sgExon6*, or *sgIntron5+6*. (I) T7 endonuclease I assay showed *sgTMEM134* efficiency in THP-1 cell line. (J) Sequence alignment results showing 2 bp insertion and 21 bp deletion in one of the *Tmem134^{-/-}* THP-1 clones and 71 bp deletion in one of the *Tmem134^{-/-}* HL-60 clones. (K) The sequence of synonymous mutated (PAM site) *TMEM134α/β* cDNA rescued in *Tmem134* KO cell lines. (L) The growth curves of endogenous *TMEM134* KO HL-60 cells with overexpressing vector, *TMEM134α* or *TMEM134β* at the indicated time points. ** $p < 0.01$, *** $p < 0.001$. P values were calculated by unpaired parametric t test. (M) The Kaplan–Meier survival curves of recipient mice transplanted with leukemic cells overexpressing vector, *TMEM134α* or *TMEM134β*. ** $p < 0.01$ (log-rank test). (N) The bar graph showing the proliferative ability of *Myc-GFP* AML cells transduced with *sgScramble*, *sgExon6*, or *sgIntron5+6*, with EdU incorporation assay. *** $p < 0.001$, p values were calculated using an unpaired parametric t test. (O) The bar graphs showed G1 score between *Hsp90aa1^{lo}* and *Hsp90aa1^{hi}* cells in murine AML (left), human AML (middle), and TCGA-LAML (right). * $p < 0.05$, p values were calculated by Wilcoxon signed-rank test. (P) The heatmap showing GSEA enrichments of cell cycle related pathways (rows) in vector, *TMEM134α* or *TMEM134β* AML cells (columns). (Q) The heatmap showing the expression levels of genes in TAKEDA_TARGET-S_OF_NUP98_HOXA9_FUSION_8D_UP pathway. The underlying data for S9B and S9L–S9O Fig can be found in [S1 Data](#).
(TIF)

S1 Table. The sequence of guide RNA for CRISPR/cas9 knock out.

(XLSX)

S2 Table. The sequence of primers for RT-PCR.

(XLSX)

S3 Table. The overview of AML patients.

(XLSX)

S1 Data. Underlying data for Figs 1–6 and S1–S6, S8 and S9.

(XLSX)

S1 Raw Images. Original scan images for Figs 6D, 6E, S5B, S5C, S9A, S9C, S9E, S9G, S9H and S9I.

(PDF)

Acknowledgments

We thank Dr. Yuquan Wei for his generous support and advice, the members of the CC-LY laboratory for their technical support and suggestions, and the Core Facilities of West China Hospital.

Ethical approval

All mouse experiments were performed in compliance with the Guide for the Care and Use of Laboratory Animals of Sichuan University and were approved by the Animal Care and Use Committee of Sichuan University.

Author Contributions

Conceptualization: Baohong Wu, Xuelan Chen, Lu Chen, Yu Liu, Chong Chen.

Data curation: Baohong Wu, Xuelan Chen, Xiangyu Pan, Xintong Deng, Mei Chen, Lu Chen, Yu Liu, Chong Chen.

Formal analysis: Baohong Wu, Xuelan Chen, Xiangyu Pan, Xintong Deng, Shujun Li, Yu Liu, Chong Chen.

Funding acquisition: Yu Liu, Chong Chen.

Investigation: Baohong Wu, Xuelan Chen, Xiangyu Pan, Lu Chen, Yu Liu, Chong Chen.

Methodology: Baohong Wu, Xuelan Chen, Jian Wang, Lu Chen, Yu Liu, Chong Chen.

Project administration: Baohong Wu, Xuelan Chen, Xiangyu Pan, Lu Chen, Yu Liu, Chong Chen.

Resources: Zhongwang Wang, Dan Liao, Jing Xu, Chengjian Zhao, Zhihong Xue, Yuan Wang, Ting Niu, Jingwen Lin, Yu Liu, Chong Chen.

Software: Xuelan Chen, Lu Chen, Yu Liu, Chong Chen.

Supervision: Baohong Wu, Xuelan Chen, Lu Chen, Yu Liu, Chong Chen.

Validation: Baohong Wu, Xuelan Chen, Xiangyu Pan, Lu Chen, Yu Liu, Chong Chen.

Visualization: Baohong Wu, Xuelan Chen, Xiangyu Pan, Lu Chen, Yu Liu, Chong Chen.

Writing – original draft: Baohong Wu, Xuelan Chen, Xiangyu Pan, Yu Liu, Chong Chen.

Writing – review & editing: Baohong Wu, Xuelan Chen, Xiangyu Pan, Lu Chen, Yu Liu, Chong Chen.

References

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990; 61:759–767. [https://doi.org/10.1016/0092-8674\(90\)90186-i](https://doi.org/10.1016/0092-8674(90)90186-i) PMID: 2188735
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature*. 1998; 396:643–649. <https://doi.org/10.1038/25292> PMID: 9872311
3. Markowitz SD, Bertagnoli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med*. 2009; 361:2449–2460. <https://doi.org/10.1056/NEJMra0804588> PMID: 20018966
4. Nowell PC. The clonal evolution of tumor cell populations. *Science (New York, N.Y.)*. 1976; 194:23–28. <https://doi.org/10.1126/science.959840> PMID: 959840
5. Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012; 481:306–313. <https://doi.org/10.1038/nature10762> PMID: 22258609
6. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. *N Engl J Med*. 2015; 373:1136–1152. <https://doi.org/10.1056/NEJMra1406184> PMID: 26376137
7. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. *Annu Rev Genomics Hum Genet*. 2002; 3:179–198. <https://doi.org/10.1146/annurev.genom.3.032802.115046> PMID: 12194988
8. Kandath C. Mutational landscape and significance across 12 major cancer types. *Nature*. 2013; 502:333–339. <https://doi.org/10.1038/nature12634> PMID: 24132290
9. Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature*. 2020; 586:763–768. <https://doi.org/10.1038/s41586-020-2819-2> PMID: 33057201
10. Bao EL. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. *Nature*. 2020; 586:769–775. <https://doi.org/10.1038/s41586-020-2786-7> PMID: 33057200
11. Terao C. Chromosomal alterations among age-related haematopoietic clones in Japan. *Nature*. 2020; 584:130–135. <https://doi.org/10.1038/s41586-020-2426-2> PMID: 32581364
12. Loh PR. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature*. 2018; 559:350–355. <https://doi.org/10.1038/s41586-018-0321-x> PMID: 29995854
13. Luo H. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. *Blood*. 2005; 106:2452–2461. <https://doi.org/10.1182/blood-2005-02-0734> PMID: 15972450

14. Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. *Science (New York, N.Y.)*. 2020; 367:405–411. <https://doi.org/10.1126/science.aax0249> PMID: 31974247
15. Kotini AG. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. *Cell Stem Cell*. 2017; 20:315–328.e317. <https://doi.org/10.1016/j.stem.2017.01.009> PMID: 28215825
16. Koh CM. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. *Nature*. 2015; 523:96–100. <https://doi.org/10.1038/nature14351> PMID: 25970242
17. Wang X. Sequential fate-switches in stem-like cells drive the tumorigenic trajectory from human neural stem cells to malignant glioma. *Cell Res*. 2021; 31:684–702. <https://doi.org/10.1038/s41422-020-00451-z> PMID: 33390587
18. van Galen P, Hovestadt V, Wadsworth li MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell*. 2019; 176:1265–1281.e1224. <https://doi.org/10.1016/j.cell.2019.01.031> PMID: 30827681
19. La Manno G. RNA velocity of single cells. *Nature*. 2018; 560:494–498. <https://doi.org/10.1038/s41586-018-0414-6> PMID: 30089906
20. Thiede C. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood*. 2006; 107:4011–4020. <https://doi.org/10.1182/blood-2005-08-3167> PMID: 16455956
21. Picelli S, Björklund ÅK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat Methods*. 2013; 10:1096–1098. <https://doi.org/10.1038/nmeth.2639> PMID: 24056875
22. Wang X, He Y, Zhang Q, Ren X, Zhang Z. Direct Comparative Analyses of 10X Genomics Chromium and Smart-seq2. *Genomics Proteomics Bioinformatics*. 2021. <https://doi.org/10.1016/j.gpb.2020.02.005> PMID: 33662621
23. Talaty P, Emery A, Holthusen K, Everly DN Jr. Identification of transmembrane protein 134 as a novel LMP1-binding protein by using bimolecular fluorescence complementation and an enhanced retroviral mutagen. *J Virol*. 2012; 86:11345–11355. <https://doi.org/10.1128/JVI.00523-12> PMID: 22855487
24. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. *Nat Rev Cancer*. 2003; 3:895–902. <https://doi.org/10.1038/nrc1232> PMID: 14737120
25. Liu Y, Gu Z, Cao H, Kaphle P, Lyu J, Zhang Y, et al. Convergence of oncogenic cooperation at single-cell and single-gene levels drives leukemic transformation. *Nat Commun*. 2021; 12:6323. <https://doi.org/10.1038/s41467-021-26582-4> PMID: 34732703
26. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature*. 2010; 463:364–368. <https://doi.org/10.1038/nature08697> PMID: 20010808
27. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martín D, et al. Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. *Cell*. 2016; 167:1398–1414 e1324. <https://doi.org/10.1016/j.cell.2016.10.026> PMID: 27863251
28. Chen L, Kostadima M, Martens JHA, Canu G, Garcia SP, Turro E, et al. Transcriptional diversity during lineage commitment of human blood progenitors. *Science*. 2014; 345:1251033. <https://doi.org/10.1126/science.1251033> PMID: 25258084
29. Wang F, Tan P, Zhang P, Ren Y, Zhou J, Li Y, et al. Single-cell architecture and functional requirement of alternative splicing during hematopoietic stem cell formation. *Sci Adv*. 2022; 8:eabg5369. <https://doi.org/10.1126/sciadv.abg5369> PMID: 34995116
30. Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. *Nature*. 2016; 531:471–475. <https://doi.org/10.1038/nature17157> PMID: 26982726
31. Picelli S, Faridani OR, Björklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc*. 2014; 9:171–181. <https://doi.org/10.1038/nprot.2014.006> PMID: 24385147
32. Han X, Wang R, Zhou Y, Fei L, Sun H, Lai S, et al. Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell*. 2018; 173:1307. <https://doi.org/10.1016/j.cell.2018.05.012> PMID: 29775597
33. Tabula Muris Consortium, Overall coordination, Logistical coordination, Organ collection and processing, Library preparation and sequencing, Computational data analysis, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature*. 2018; 562:367–372.
34. Nestorowa S, Hamey FK, Pijuan Sala B, Diamanti E, Shepherd M, Laurenti E, et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. *Blood*. 2016; 128:e20–e31. <https://doi.org/10.1182/blood-2016-05-716480> PMID: 27365425

35. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med*. 2004; 350:1617–1628. <https://doi.org/10.1056/NEJMoa040465> PMID: 15084694
36. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science (New York, N.Y.)*. 2014; 344:1396–1401. <https://doi.org/10.1126/science.1254257> PMID: 24925914